Clopidogrel compared with other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention: clinical and cost-effectiveness analyses.
Year: 2012
Type: article
Abstract: In Canada, cardiovascular diseases (CVDs) (coronary disease, cerebrovascular disease, and peripheral arterial disease [PAD]) causes illness, disability, and death,1 which leads to associated high health care costs. As the population ages, the number of Canadians with CVD is likely to increase, further increasing the health care system’s expenditures.
Atherosclerosis is a type of CVD that results from the buildup of plaque over time. Patients, whose coronary arteries have become occluded from plaque, may undergo a procedure known as percutaneous coronary intervention (PCI) to unblock the artery. In PCI, a bare-metal or drug-coated stent may be inserted through a catheter to prop open the artery and restore blood flow. Stents, by their nature, can increase the risk of clots from platelet adhesion, so an antiplatelet agent is typically prescribed to reduce this risk. Dual clopidogrel and ASA therapy is the most common approach prescribed by many physicians to prevent stent thrombosis in patients with PCI.2
However, clopidogrel is an expensive drug relative to other treatments, and the number of reimbursement requests for clopidogrel submitted to Canadian publicly funded drug plans is increasing. Given limited health care resources, an assessment of the clinical effectiveness and cost-effectiveness of clopidogrel is needed to inform policy-makers about the sustainability of current reimbursement policies.
Objective
The aim of this report is to compare clopidogrel with other antiplatelet agents for the secondary prevention of vascular events in adults undergoing percutaneous coronary intervention (PCI).
Source: Europe PMC (PubMed Central)
Authors: Sy Chen, E Russell, S Banerjee, B Hutton, A Brown, K Asakawa, L McGahan, M Clark, M Severn, J Cox, M Sharma
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1271288749